Petros Pharmaceuticals Inc (PTPI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -14,319 | -8,163 | -20,038 | -8,987 | -20,586 |
| Depreciation Amortization | 5,911 | 3,415 | 13,176 | 6,891 | 6,814 |
| Income taxes - deferred | N/A | N/A | N/A | N/A | -1,432 |
| Accounts receivable | 1,819 | -144 | 516 | 2,549 | -2,750 |
| Accounts payable and accrued liabilities | 616 | -93 | -2,752 | -1,052 | 2,222 |
| Other Working Capital | 4,527 | 625 | -3,091 | -1,694 | -5,601 |
| Other Operating Activity | -1,156 | -3,266 | -609 | -9,569 | 6,028 |
| Operating Cash Flow | $-2,603 | $-7,627 | $-12,797 | $-11,862 | $-15,305 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -25 | N/A | N/A | N/A | -5 |
| Investing Cash Flow | $-25 | $N/A | $N/A | $N/A | $-5 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 38,092 |
| Debt Repayment | -765 | -1,464 | -1,624 | -7,188 | -6,716 |
| Common Stock Issued | N/A | N/A | N/A | 25,757 | 21 |
| Other Financing Activity | -6,234 | 13,001 | 0 | 0 | -1,093 |
| Financing Cash Flow | $-6,999 | $11,537 | $-1,624 | $18,570 | $30,304 |
| Beginning Cash Position | 13,337 | 9,426 | 23,848 | 17,140 | 2,146 |
| End Cash Position | 3,710 | 13,337 | 9,426 | 23,848 | 17,140 |
| Net Cash Flow | $-9,627 | $3,911 | $-14,421 | $6,708 | $14,994 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,603 | -7,627 | -12,797 | -11,862 | -15,305 |
| Capital Expenditure | -25 | N/A | N/A | N/A | -5 |
| Free Cash Flow | -2,628 | -7,627 | -12,797 | -11,862 | -15,310 |